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Introduction {#sec1}
============

Macroautophagy (hereafter referred to as autophagy) acts as a homeostatic pathway at both the cellular and organismal levels ([@bib44]). The finely tuned execution of this multistep process (ensured by the coordinated activity of specifically committed Atg proteins) eventually culminates in the formation of a double-membrane organelle, the autophagosome, in which bulk portions of the cytoplasm or specific organelles are engulfed prior to their lysosomal hydrolase-mediated degradation ([@bib20]). Autophagy may be considered as one of the major anti-aging mechanisms because it assures recycling (and hence rejuvenation) of damaged cytoplasmic components, including entire organelles such as mitochondria ([@bib48], [@bib54], [@bib62]). Manipulations aiming at restoring or inducing autophagy can reduce the incidence of age-related disease and extend health span and lifespan ([@bib36]). The nature of these interventions can be nutritional (i.e., fasting or caloric restriction) ([@bib22], [@bib35]), behavioral (i.e., physical activity) ([@bib21]), or pharmacological. Thus, mTORC1 inhibition by rapalogs ([@bib32]), activation of sirtuin-1 (SIRT1) with resveratrol ([@bib65]), and supplementation of the natural polyamine spermidine ([@bib12]) extend lifespan in various model organisms in an autophagy-dependent manner ([@bib36]). Importantly, overexpression of the autophagy essential gene Atg5 is sufficient to expand lifespan in mice ([@bib52]), indicating that autophagy is not only necessary but even sufficient to enhance longevity.

Culture of cells in nutrient-free conditions, as well as fasting regimens, leads to a reduction in the global levels of protein acetylation ([@bib13], [@bib38]). Reduced acetylation may be explained by the diminution in the activity of nuclear and cytoplasmic lysine-acetyltransferases (KAT) secondary to a decrease in the nucleocytosolic levels of acetyl coenzyme A (CoA), which is the sole donor of acetyl groups ([@bib49]). As a consequence, blockade of acetyl CoA biosynthesis has the same functional consequence as inhibition of acetyltransferases or activation of the deacetylase activity of sirtuins ([@bib37]) insofar that it triggers autophagy ([@bib38]). Chemically unrelated agents, including anacardic acid, hydroxycitrate, resveratrol, and spermidine ([@bib50]), share the capacity to reduce protein acetylation and have been classified as caloric restriction mimetics (CRMs). CRMs such as spermidine have widespread anti-aging effects ([@bib14], [@bib51]).

One of the major acetyltransferases that senses cytosolic acetyl CoA levels is adenovirus early region 1A (E1A)-binding protein p300, EP300, which also acts as a master repressor of autophagy ([@bib37]). Of note, the autophagy inducer spermidine competes with acetyl CoA for binding to the catalytic site of EP300 and, therefore, limits its activity ([@bib45], [@bib50]). Recently, aspirin has been shown to inhibit the enzymatic activity of EP300 as well ([@bib59]). Aspirin (acetylsalicylate), the pro drug of salicylate (which is rapidly formed *in vivo* through the action of blood and tissue acetylsalicylate hydrolases) ([@bib1]), is probably the pharmacological agent that has the most pleiotropic effects on human health, as it has broad anti-arteriosclerotic and cancer-preventive effects ([@bib2], [@bib46], [@bib55]). Beyond its inhibitory action on cyclooxygenases, resulting in the inhibition of prostaglandin synthesis, aspirin affects multiple signal transduction pathways. For example, aspirin reportedly inhibits the activation of the pro-inflammatory transcription factor nuclear factor kappa light-chain enhancer of activated B cell (NF-κB) ([@bib31]), and it directly activates the nutrient sensor protein kinase AMP activated (PRKAA1), better known as AMPK ([@bib19]).

Here we addressed the question as to whether aspirin might have a broad autophagy-inducing effect and whether this effect might be explained by EP300 inhibition. We demonstrate that aspirin fails to modulate autophagic flux in cells lacking EP300 or cells in which EP300 has been engineered to avoid aspirin binding to the acetyl CoA-binding pocket of the enzyme. As a confirmation of the evolutionarily conserved nature of this process, we demonstrate that aspirin failed to further induce autophagy in *Caenorhabditis elegans* strains deficient for the EP300 homolog CBP-1 or the essential autophagy gene products ATG7 and BEC-1.

Results {#sec2}
=======

Salicylate Inhibits the Acetyltransferase Activity of EP300 {#sec2.1}
-----------------------------------------------------------

Anacardic acid (AA, also known as 6-pentadecylsalicylic acid) represents the prototypical inhibitor of acetyltransferases from the EP300/PCAF family. In a competitive interaction, the salicylate group of AA displaces the pyrophosphate group of CoA from the KAT domain of EP300 ([@bib17]). We investigated the possibility that the active aspirin metabolite salicylate itself would inhibit EP300 acetyltransferase activity via a similar mechanism as AA. In a cell-free-based assay, salicylate inhibited the enzymatic activity of recombinant EP300 protein, resulting in reduced acetylation of its natural substrate histone H3 on lysine 56 (H3K56) ([Figures 1](#fig1){ref-type="fig"}A and 1B). Importantly, the inhibition of EP300 activity by salicylate was comparable to that of AA or the synthetic EP300 inhibitor C646 ([Figures 1](#fig1){ref-type="fig"}A and 1B). This inhibitory effect was achieved at a physiological concentration of acetyl CoA (AcCoA), but it was attenuated by high-dose AcCoA, in line with the idea that it occurred through a competitive mechanism ([Figures 1](#fig1){ref-type="fig"}A and 1B), as recently proposed ([@bib59]). Consistently, the administration of salicylate to two different cultured cell lines inhibited the EP300-mediated acetylation of histone 2A (H2AK5) ([Figures 1](#fig1){ref-type="fig"}C and 1E) and H3K56 ([Figures 1](#fig1){ref-type="fig"}D and 1F) in a dose-dependent manner. Altogether, these data support the hypothesis that salicylate acts as a direct competitive inhibitor of EP300.Figure 1Salicylate Inhibits EP300 Acetyltransferase by Competing with AcCoA(A and B) Direct inhibition of EP300 acetyltransferase activity by salicylate. Recombinant EP300 protein was incubated with its substrate histone H3 in the presence of AcCoA, salicylate (5 mM), anacardic acid (AA, 50 μM), or C646 (10 μM), followed by immunoblotting to detect H3 acetylation on lysine 56 (A) and quantification (B) of 4 independent experiments (means ± SEM; ^∗^p \< 0.05 and ^∗∗∗^p \< 0.001, one-way ANOVA compared to 10 μM AcCoA control group; ^\#\#\#^p \< 0.001, one-way ANOVA compared to 100 μM AcCoA; FC, fold change).(C and D) Salicylate inhibits EP300 activity toward its natural substrates. Human colorectal cancer HCT116 (C) and human osteosarcoma U2OS cells (D) were incubated for 16 hr with the indicated concentration of sodium salicylate and subjected to immunoblotting to evaluate H2A acetylation on lysine 5 (C) and H3 acetylation on lysine 56 (D) (quantified in E and F). Nutrient-free (NF) medium was used as a negative control of acetylation. Representative images of one experiment are shown.(E and F) Quantification of data depicted in (C) and (D) (means ± SEM; ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001, one-way ANOVA compared to control group).

Salicylate-Induced Autophagy Depends on EP300 Inhibition {#sec2.2}
--------------------------------------------------------

Owing to its ability to directly acetylate key autophagic machinery components, such as Atg5, Atg7, LC3 ([@bib33]), and BECN1 ([@bib61]), EP300 can transduce AcCoA availability into autophagy inhibition. Based on these findings, we determined whether salicylate would induce autophagy through an EP300-dependent mechanism. U2OS cells stably transfected with a fusion protein of GFP and microtubule-associated proteins 1A/1B light chain 3B (GFP-LC3) manifested the formation of cytoplasmic GFP-LC3 puncta upon treatment with salicylate ([Figure 2](#fig2){ref-type="fig"}A). Importantly, the increase in number of GFP-LC3 dots was even more prominent when autophagosome-lysosome fusion was impaired by treatment with bafilomycin A1 (BafA1), indicating that salicylate induced autophagic flux ([Figure 2](#fig2){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}). Consistently, human colorectal cancer HCT116 cells treated with two different doses of sodium salicylate exhibited enhanced lipidation of LC3 (as indicated by an increase in its electrophoretic mobility), both in the presence and in the absence of a lysosomal inhibitor ([Figure 2](#fig2){ref-type="fig"}B; [Table S1](#mmc2){ref-type="supplementary-material"}). In line with the observation that salicylate bona fide promotes autophagic flux, the addition of this compound to cell cultures caused a diminution in the global levels of sequestosome-1 (SQSTM1/p62) ([Figure 2](#fig2){ref-type="fig"}B; [Table S1](#mmc2){ref-type="supplementary-material"}) ([@bib30]).Figure 2Aspirin Stimulates Autophagic Flux in Cultured Cells(A and B) *In vitro* effects of the aspirin metabolite salicylate.(A) U2OS cells expressing GFP-LC3 were treated with salicylate (5 mM), anacardic acid (AA, 50 μM), or C646 (10 μM) in the presence or absence of the lysosomal inhibitor bafilomycin A1 (Baf A1), followed by quantitation of GFP-LC3-positive puncta. Representative images (left panel) and quantitation (right panel) of the number of GFP-LC3 puncta per cell are depicted (^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001, unpaired t test compared with respective control condition). Data represent means ± SD from one representative experiment (n = 3).(B) HCT116 cells were incubated for 16 hr in the presence of growing concentrations of salicylate. Representative immunoblots of 4 independent experiments show the LC3I-to-LC3II conversion (in the presence or absence of BafA1) and depletion of SQSTM1/p62.(C and D) Analysis of autophagy-dependent long-lived protein (LLP) degradation upon treatment with salicylate.(C) 3-methyladenine (3-MA)-sensitive degradation of \[^14^C\]-valine-labeled long-lived proteins was determined in HCT116 cells upon treatment with salicylate. Values indicate means ± SD from one representative experiment (n = 3; ^∗∗^p \< 0.01, unpaired t test compared to control condition).(D) Autophagy-mediated degradation of L-azidohomoalanine (L-AHA)-labeled proteins was assessed in U2OS cells after treatment with salicylate or Rapamycin (Rapa) in the presence or absence of 3-methyladenine. Maximum fluorescence intensity (MFI) values represent means ± SD from one representative experiment (n = 3; ^∗^p \< 0.05, unpaired t test compared to Co group).

In addition, salicylate promoted the autophagy-dependent degradation of long-lived protein, as detected by assessing protein turnover in cells in which proteins were labeled radioactively with \[^14^C\]-valine ([@bib3], [@bib10]) ([Figure 2](#fig2){ref-type="fig"}C). Very similar results were obtained when protein turnover was measured after pulse-labeling cells by means of the amino acid analog L-azidohomoalanine (L-AHA), yielding azido-modified proteins that could be visualized by chemoselective ligation with a fluorescent alkyne probe ([@bib64]) ([Figure 2](#fig2){ref-type="fig"}D). Importantly, the enhanced protein turnover elicited by salicylate treatment was reversed by the simultaneous addition of the autophagy inhibitor 3-methyladenine to the cell cultures (3-MA), further strengthening the notion that salicylate stimulates autophagic flux ([Figures 2](#fig2){ref-type="fig"}C and 2D). Salicylate uptake by cells is mediated by sodium monocarboxylate transporters ([@bib16]), and cell line-dependent differences in the expression of these carriers may be at the origin of the relatively delayed action of this compound on autophagy and EP300 inhibition. We hence assessed autophagy induction upon short-term treatment with growing concentrations of the cell-permeable salicylate ester ethyl-salicylate. This agent rapidly induced autophagic flux as it inhibited EP300 acetyltransferase activity ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C; [Table S1](#mmc2){ref-type="supplementary-material"}).

Incubation of cells with salicylate inhibited the activity of mTORC1 complex (as monitored by the decreased phosphorylation of mTORC1 substrate ribosomal protein S6 kinase beta-1 RPS6KB1, also known as p70^S6K^) and stimulated PRKAA function (as indicated by its increased phosphorylation on Thr 172 by upstream kinases) ([Figure S1](#mmc1){ref-type="supplementary-material"}D; [Table S1](#mmc2){ref-type="supplementary-material"}). This event might be sufficient for triggering autophagy, because PRKAA can directly phosphorylate at least two pro-autophagic proteins, namely, the unc-51-like autophagy-activating kinase 1 (ULK1) ([@bib11], [@bib29]) and BECN1 ([@bib27]). However, the pro-autophagic effect of salicylate was still observable when the expression of PRKAA α1 subunit was attenuated by transfection of specific small interfering RNAs (siRNAs) ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F; [Table S1](#mmc2){ref-type="supplementary-material"}). In accord with previous findings ([@bib9]), salicylate still could induce autophagy in mouse embryonic fibroblasts (MEFs) lacking both the α1 and α2 PRKAA subunits (genotype *PRKAAα1*^−/−^ *PRKAAα2*^−/−^) ([Figure S1](#mmc1){ref-type="supplementary-material"}G; [Table S1](#mmc2){ref-type="supplementary-material"}).

Next, we investigated whether modulation of EP300 activity would be responsible for the pro-autophagic activity of this compound. Epistatic analyses indicated that salicylate was unable to further increase autophagic flux in conditions of EP300 knockout ([Figures 3](#fig3){ref-type="fig"}A and 3B; [Figure S2](#mmc1){ref-type="supplementary-material"}A; [Table S1](#mmc2){ref-type="supplementary-material"}) or knockdown ([Figure S2](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc2){ref-type="supplementary-material"}), suggesting that it stimulates autophagy through EP300 inhibition. In contrast, rapamycin was able to stimulate autophagy in conditions of EP300 depletion ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Interestingly, EP300-knockout cells failed to exhibit differences in PRKAA activation levels or upon salicylate treatment when compared to their wild-type (WT) counterparts, suggesting that these pathways act independently of each other ([Figure S2](#mmc1){ref-type="supplementary-material"}D).Figure 3EP300 Inhibition Is Epistatic to Salicylate-Induced Autophagy(A and B) Administration of increasing doses of salicylate to human HCT116 colorectal cancer cells stably expressing GFP-LC3 induces autophagy in wild-type (WT), yet it fails to further stimulate autophagy in EP300 knockout (KO-EP300) cells. Representative images (A, from Co versus 5-mM salicylate dose in the presence of bafilomycin A1) and quantitation of the number of GFP-LC3 puncta (B) are reported. Results (means ± SD) are from one representative experiment (^∗^p \< 0.05, unpaired t test compared with respective control conditions; ^∗∗^p \< 0.01, unpaired t test compared with respective control conditions; ^∗∗∗^p \< 0.001, unpaired t test compared with respective control conditions; ^\#\#\#^p \< 0.001, unpaired t test compared with WT control cells).(C and D) Computational docking model of the interactions between the CoA-binding site of EP300 with Lys-CoA (C) or salicylate (D). Two amino acid residues suggested to be important for the interaction with salicylate, but not for that with AcCoA, were mutated (Y1414A and W1466K), as described in the corresponding [Experimental Procedures](#sec4){ref-type="sec"}.(E and F) HCT116 KO-EP300 cells, untagged (E) or stably expressing GFP-LC3 (F), were transfected with a vector carrying wild-type (WT), Y1414A, W1466K, or double-mutated (DM) forms of EP300. In EP300-KO HCT116 cells transfected with the W1466K or EP300 DM forms, salicylate-induced autophagy is partially or completely abrogated, respectively, as measured by following the LC3I-to-LC3II conversion by immunoblotting (E) and the formation of GFP-LC3 positive puncta (in the presence or absence of BafA1) (F). Representative immunoblots (E) and automated videomicroscopy-based quantitation of the number of GFP-LC3 puncta/cell (F) are depicted. Rapamycin (R) was used as a positive control of autophagy induction (means ± SD). One representative experiment is shown (n = 3; ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001, unpaired t test compared with respective control group).(G) Salicylate reduces the EP300-dependent acetylation of autophagic protein LC3. HCT116 cells stably expressing GFP-LC3 were incubated for 16 hr with the indicated concentration of salicylate followed by GFP-Trap-based immunoprecipitation. NF medium was used as a negative control of LC3 acetylation. Acetylation status of GFP-LC3 immunoprecipitate was assessed by means of an antibody recognizing acetylated residues on proteins (left panel) and quantified (right panel). Values represent means ± SEM from three independent experiments (normalized on immunoprecipitated GFP levels) (^∗∗∗^p \< 0.001 and ^∗∗^p \< 0.01, one-way ANOVA).

Molecular modeling using the bi-substrate inhibitor Lys-CoA ([@bib4]) docking site of EP300 ([Figure 3](#fig3){ref-type="fig"}C) suggested that the introduction of two point mutations would be compatible with AcCoA binding yet prevent salicylate to access the catalytic site ([Figure 3](#fig3){ref-type="fig"}D). The knockout (KO)-EP300 HCT116 cells transfected with WT EP300 responded to salicylate by increasing LC3 lipidation ([Figure 3](#fig3){ref-type="fig"}E) or generation of LC3 puncta ([Figure 3](#fig3){ref-type="fig"}F). In contrast, replacement of endogenous EP300 by the EP300 Y1414A/W1466K double mutant (DM) was unable to restore autophagy induction by salicylate, whereas single W1466K mutation partially impaired autophagic flux ([Figures 3](#fig3){ref-type="fig"}E and 3F). In line with the prediction of the molecular model, the double-mutated form of EP300 was still able to acetylate its specific substrates (and hence to transfer the acetyl moiety of AcCoA on protein), contrasting with its inability to functionally interact with salicylate ([Figure S2](#mmc1){ref-type="supplementary-material"}E).

As a master repressor of the autophagic pathway, EP300 mediates the acetylation of several components of autophagic machinery, including that of LC3 ([@bib25], [@bib56]). Indeed, LC3 was deacetylated upon salicylate treatment ([Figure 3](#fig3){ref-type="fig"}G), further suggesting that salicylate-induced autophagy occurred through EP300 inhibition.

Injection of aspirin into mice induced signs of autophagy *in vivo* in various organs, including heart ([Figure 4](#fig4){ref-type="fig"}A; [Figures S3](#mmc1){ref-type="supplementary-material"}A--S3F) and liver ([Figure 4](#fig4){ref-type="fig"}B; [Figures S4](#mmc1){ref-type="supplementary-material"}A--S4F), as suggested by LC3 lipidation, SQSTM1/p62 degradation, and reduction in RPS6KB1 phosphorylation (statistically significant in the heart and with a trend in the liver). These changes were detectable as early as 1 hr post-injection of salicylate, and they were paralleled by a transient inhibition of EP300 activity, as indicated by the reduced acetylation of its natural substrate H3K56 ([Figures 4](#fig4){ref-type="fig"}A and 4B). However, the phosphorylation of PRKAA and that of its substrate ACACA occurred at later time points (starting at 6 hr), suggesting that PRKAA activation is unlikely to be involved in the early phase of autophagy induction by aspirin. However, these results do not exclude that PRKAA intervenes in later aspirin effects, which involve complex physiological changes, including non-cell-autonomous signals ([@bib23]). Importantly, the pro-autophagic effect of salicylate was observed even when the degradation of lysosomal content was inhibited by the injection of leupeptin 2 hr before sacrifice, thus corroborating the evidence that aspirin stimulates autophagic flux in the heart ([Figure 4](#fig4){ref-type="fig"}C; [Figure S3](#mmc1){ref-type="supplementary-material"}G) and in the liver ([Figure 4](#fig4){ref-type="fig"}D; [Figure S4](#mmc1){ref-type="supplementary-material"}G).Figure 4Induction of Autophagy by Acetylsalicylic Acid *In Vivo*(A and B) Representative immunoblots (n = 3 mice per condition, n = 3 experiments) showing LC3I-to-LC3II conversion and depletion of the autophagic substrate SQSTM1/p62 in the heart (A) and in the liver (B) (1, 3, and 6 hr after intraperitoneal (i.p.) injection of 100 mg/kg aspirin). Autophagy induction *in vivo* is paralleled by a transient decrease in H3K56 acetylation, precedes PRKAA activation (as monitored by upstream kinase-dependent phosphorylation on Thr172 and an increase in PRKAA-mediated ACACA phosphorylation on Ser79), and it is accompanied by a reduction in the mTORC1 substrate PRS6K1. GAPDH levels were monitored to ensure equal protein content. Quantification of (A) and (B) are shown in [Figures S3](#mmc1){ref-type="supplementary-material"}A--S3F and [S4](#mmc1){ref-type="supplementary-material"}A--S4F, respectively.(C and D) Representative immunoblots (n = 2 experiments, n = 3 mice per group) showing LC3I-to-LC3II conversion in the presence or absence of the protease inhibitor leupeptin (Leup) in the heart (C) and liver (D) 6 hr after aspirin treatment. Quantifications are presented in [Figures S3](#mmc1){ref-type="supplementary-material"}G and [S4](#mmc1){ref-type="supplementary-material"}G, respectively.(E and F) Long-term aspirin treatment enhances autophagic flux in the heart and stimulates mitophagy.(E) Transgenic mice expressing the tandem-fluorescent mRFP-GFP-LC3 (Tg-tf-LC3) were treated for 2 weeks with 25 mg/kg aspirin by oral gavage, and autophagic flux was assessed by the injection of chloroquine (10 mg/kg) 4 hr prior to euthanasia. Representative images of fluorescent GFP-LC3 puncta and mRFP-puncta are shown in the left panel. Arrows, autophagosomes; arrowheads, autolysosomes. Values in the right panel represent mean number of autophagosomes (yellow bars) and autolysosomes (red bars) per cell ± SD from one representative experiment (^∗∗∗^p \< 0.001 and \#\#p \< 0.01, one-way ANOVA compared to respective control conditions).(F) Evaluation of mitochondrial autophagy by transgenic Mito-Keima mice. 2-month-old C57BL/6J mouse hearts were examined in the control versus aspirin-treated group (n = 3 mice/group). Representative images of Mito-Keima green (457 nm), Mito-Keima red (561 nm), the merged image, and a ratiometric image of red-to-green Mito-Keima (561/457 nm) indicating mitophagy are shown (left panel) and quantified (right panel). Values represent means ± SD from one representative experiment (^∗∗∗^p \< 0.001, unpaired t test compared to control group). Scale bar, 50 μm.

Next we assessed the effect of protracted oral administration of aspirin (2 weeks) on cardiac autophagy in transgenic mice overexpressing the tandem construct GFP-RFP-LC3 in cardiomyocytes ([@bib14], [@bib18]). Aspirin treatment resulted in an increase in the number of red/green fluorescent (autophagosomes) and red fluorescent puncta (autolysosomes), suggestive of autophagy induction in the heart ([Figure 4](#fig4){ref-type="fig"}E). This aspirin-triggered increase in LC3 puncta also occurred in mice treated with chloroquine, further supporting the idea that aspirin indeed stimulated autophagic flux *in vivo* ([Figure 4](#fig4){ref-type="fig"}E). Aspirin also potently stimulated one particular type of organelle-specific autophagy, mitophagy ([@bib58]), in the heart, as monitored by means of a transgene-encoded biosensor, mito-Keima (mt-Keima) ([@bib26], [@bib57]), a mitochondrion-targeted protein that undergoes a pH-dependent excitation shift when it localizes in the acidic lysosomal compartment ([Figure 4](#fig4){ref-type="fig"}F).

Aspirin induced LC3 lipidation and SQSTM1 degradation in most organs that we investigated and in particular in heart ([Figure 4](#fig4){ref-type="fig"}A), liver ([Figure 4](#fig4){ref-type="fig"}B), muscle ([Figure S5](#mmc1){ref-type="supplementary-material"}A), and colon ([Figure S5](#mmc1){ref-type="supplementary-material"}E), but not in brain ([Figure S5](#mmc1){ref-type="supplementary-material"}I) and kidney ([Figure S6](#mmc1){ref-type="supplementary-material"}D). It is known that, when orally administered to healthy human volunteers ([@bib6]) or rodents ([@bib24]), aspirin is rapidly converted into its active metabolites, in particular salicylate, which peaks around 20--30 min in the plasma. However, aspirin metabolism has not been extensively studied by modern metabolomics methods. At 1 hr after intraperitoneal administration of aspirin, significant changes in the metabolome of several organs, including heart ([Figure 5](#fig5){ref-type="fig"}A; [Table S2](#mmc3){ref-type="supplementary-material"}), liver ([Figure 5](#fig5){ref-type="fig"}D; [Table S2](#mmc3){ref-type="supplementary-material"}), skeletal muscle ([Figure S5](#mmc1){ref-type="supplementary-material"}B; [Table S2](#mmc3){ref-type="supplementary-material"}), colon ([Figure S5](#mmc1){ref-type="supplementary-material"}F; [Table S2](#mmc3){ref-type="supplementary-material"}), brain ([Figure S5](#mmc1){ref-type="supplementary-material"}J; [Table S2](#mmc3){ref-type="supplementary-material"}), plasma ([Figure S6](#mmc1){ref-type="supplementary-material"}A; [Table S2](#mmc3){ref-type="supplementary-material"}), and kidney ([Figure S6](#mmc1){ref-type="supplementary-material"}E; [Table S2](#mmc3){ref-type="supplementary-material"}) occurred, as monitored by mass spectrometry. More importantly, we assessed the presence of peaks indicating the formation of aspirin metabolites in these organs after administering either unlabeled aspirin or \[^13^C\]-labeled aspirin, while searching for molecular entities that differ in their mass by exactly 1 Da ([Figures 5](#fig5){ref-type="fig"}B and 5E; [Figures S5](#mmc1){ref-type="supplementary-material"}C, S5G, S5K, [S6](#mmc1){ref-type="supplementary-material"}B, and S6F). Several among these unidentified molecular entities were at least as abundant as salicylate ([Figures 5](#fig5){ref-type="fig"}C and 5F; [Figures S5](#mmc1){ref-type="supplementary-material"}D, S5H, S5L, [S6](#mmc1){ref-type="supplementary-material"}C, and S6G), and most of them were organ specific ([Figure 5](#fig5){ref-type="fig"}G). Salicylate was one among 13 aspirin metabolites that were clearly detectable in all investigated organs ([Figure 5](#fig5){ref-type="fig"}H; [Table S2](#mmc3){ref-type="supplementary-material"}). In line with our *in vitro* observations and with the evidence that, in patients taking up to 3 g aspirin/day, salicylate reaches 1--3 mM concentration in plasma ([@bib59]), a dose range in which this molecule exhibits EP300 inhibitory and pro-autophagic properties, salicylate thus likely represents one of the principal metabolites responsible for aspirin activity. At this stage, it is not clear why some organs are refractory to aspirin-mediated induction of autophagy.Figure 5Metabolomics Analysis of Aspirin-Derived MetabolitesThe 6-week old C57BL/6 mice were injected with unlabeled aspirin (Asp) or \[^13^C\]-labeled aspirin (^13^CAsp) (100 mg/kg, i.p.), followed by mass spectrometry.(A and D) Volcano plots relative to metabolites detected in the heart (A) and in the liver (D) after unlabeled aspirin injection. Log2FC of Asp/Co-downregulated (green) or -upregulated (blue) metabolites with p value \< 0.05 is represented.(B and E) Volcano plots relative to metabolites detected in the heart (B) and in the liver (E) after \[^13^C\]-labeled aspirin injection. Log2FC of ^13^CAsp/Asp-downregulated (green) or -upregulated (red) metabolites with p value \< 0.05 is depicted.(C and F) Comparison between ^13^CAsp/Asp (red) and Asp/Co (blue). Log2FC significantly changed (p value \< 0.05) in the heart (C) and in the liver (F) is graphed. The blue box highlights salicylate, which represents a commonly upregulated metabolite in all organs assessed.(G and H) Heatmap (Log2FC) of ^13^CAsp/Asp metabolites in different organs (G) is shown. \[^13^C\]-Aspirin administration allows the identification of bona fide aspirin-derived metabolites, which are distributed in an organ-specific fashion. Common upregulated metabolites are highlighted with a blue box. Magnification is shown in (H). Pre-annotated metabolites are as follows: SA\[^∗^\]\@4.14, salicylic acid, positive mode; GenA\[^∗^\]\@4.07(-), gentisic/2-pyrocatechuic acid; SA\[^∗^\]\@5.00(-), salicylic acid, negative mode; SuA\[^∗^\]\@4.57(-), salicyluric acid; and SaGlc\[^∗^\]\@3.76(-), salicylate glucuronide. Details are available in [Table S2](#mmc3){ref-type="supplementary-material"}.

Aspirin Induces Autophagy in *C. elegans* via EP300 Inhibition {#sec2.3}
--------------------------------------------------------------

Upon treatment with aspirin, autophagic puncta (visualized as a fusion protein between the LC3 worm ortholog LGG-1 and GFP) were significantly upregulated in nematode embryos ([Figure 6](#fig6){ref-type="fig"}A). The aspirin-induced increase in LGG-1 puncta was accompanied by the degradation of the autophagic substrate SQST-1 ([Figure 6](#fig6){ref-type="fig"}B), and this was still observed after the addition of BafA1, as compared to BafA1-only-treated animals ([Figure 6](#fig6){ref-type="fig"}C), yet lost upon silencing of the autophagy essential genes *bec-1* and *atg-7* in the intestine of adult animals ([Figure 6](#fig6){ref-type="fig"}D). Consistent with data obtained in mammalian cells, RNAi-mediated silencing of *cbp-1* (the *C. elegans* ortholog of EP300) was sufficient to stimulate autophagy ([Figure 6](#fig6){ref-type="fig"}E). Importantly, autophagy mediated by *cbp-1* silencing could not be further enhanced by aspirin treatment, indicating that *cbp-1* inhibition was epistatic to aspirin-induced autophagy ([Figure 6](#fig6){ref-type="fig"}E). Salicylate was able to trigger autophagy in nematodes to an extent comparable with aspirin treatment ([Figure 6](#fig6){ref-type="fig"}F). In agreement with the notion that aspirin specifically promotes mitophagy in cardiomyocytes, we found that silencing of *dct-1*, a putative ortholog of the mammalian NIX/BNIP3L and BNIP3 and a key mediator of longevity and mitophagy in *C. elegans* ([@bib47]), abolished aspirin-induced autophagy ([Figure 6](#fig6){ref-type="fig"}G), suggesting that aspirin engages in selective autophagic degradation of mitochondria in nematodes. In support of this observation, we demonstrated that aspirin treatment induced the selective autophagic degradation of the mitochondrial targeted Rosella (mt-Rosella) biosensor ([Figure 6](#fig6){ref-type="fig"}H).Figure 6Aspirin Activates Autophagy in *C. elegans* and Reduces Aging in an Autophagy Gene-Dependent Manner(A) Representative confocal images (left panel) of GFP::LGG-1-expressing embryos treated with 1 mM aspirin compared to vehicle and quantification of GFP::LGG-1 puncta per embryo (right panel). Scale bar, 10 μm. Data represent means ± SEM of at least 15 images obtained across 2 independent experiments (^∗∗∗^p \< 0.001, unpaired t test compared to vehicle-treated nematodes).(B) Aspirin administration promotes proficient autophagic flux, as monitored by the reduction in levels of SQST-1/p62 autophagic substrate in the pharyngeal region of SQST-1::GFP transgenic animals at day 1 of adulthood. Representative images (left panel) and quantification (right panel) are shown. Scale bar, 20 μm. Data represent means ± SEM of n = 52 worms per group, pooled from three independent experiments (^∗∗^p \< 0.01, unpaired t test).(C) Aspirin stimulates autophagic flux. Representative confocal images (left panel) and quantification (right panel) of GFP::LGG-1 puncta in the hypodermal seam cells of L3--L4 larvae treated or not from the L4 stage of the first generation with 1 mM aspirin in the absence or in the presence of bafilomycin A1 (100 μg/mL). Scale bar, 10 μm. Data represent means ± SEM of n = 196--329 seam cells, pooled from two independent experiments (^∗∗∗^p \< 0.001, one-way ANOVA compared to vehicle -- BafA1 treatment; ^\#\#\#^p \< 0.001, one-way ANOVA compared to vehicle + BafA1 treatment).(D) Administration of aspirin induces the autophagy-dependent increase of p~*nhx-2*~mCherry::LGG-1 puncta in the intestine of 2-day-old adults, which is lost upon siRNA-mediated depletion of BEC-1 and ATG-7. Epifluorescence images are depicted in the left panel (magnification indicates mCherry::LGG-1 puncta as detected in aspirin-treated worms) and quantified in the right panel. Scale bar, 100 μm. Data represent means ± SEM of n = 15--28 worms per group, pooled from two independent experiments (^∗∗∗^p \< 0.001, one-way ANOVA compared to vehicle Co *RNAi*).(E) CBP-1 depletion is epistatic to aspirin-induced autophagy. RNAi-driven elimination of *cbp-1* in transgenic animals expressing the GFP::LGG-1 reporter leads to an increase in the number of GFP::LGG-1 puncta, which are not further increased by aspirin administration. Representative confocal images (left panel) and corresponding quantification (right panel) are shown. Scale bar, 10 μm. Data represent means ± SEM (^\#\#^p \< 0.005 and ^∗∗^p \< 0.01, unpaired t test compared to Co *RNAi*-vehicle condition).(F) Salicylate induces autophagy in *C. elegans*. Representative confocal images (left panel) and corresponding quantification (right panel) of GFP::LGG-1 puncta in transgenic embryos treated with vehicle or salicylate (1 mM). Vehicle bar is shared with experiments depicted in (A) as assays were conducted in parallel. Data represent means ± SEM of at least 15 images obtained in 2 independent experiments (^∗∗∗^p \< 0.001, unpaired t test compared to vehicle-treated nematodes).(G) Knockdown of *dct-1*, a putative ortholog to the mammalian NIX/BNIP3L and BNIP3, reduces the number of GFP::LGG-1-positive foci in the epidermis of aspirin-treated young adult wild-type animals. Representative confocal images (left panel) and corresponding quantification (right panel) are depicted. Scale bar, 10 μm. Values represent means ± SEM (^∗∗^p \< 0.01, unpaired t test compared with Co *RNAi* vehicle; \#p \< 0.05, unpaired t test compared with Co *RNAi* aspirin). Co *RNAi* vehicle and aspirin bars are shared with data depicted in (E), as assays were conducted in parallel.(H) Mitophagy is induced in nematodes treated with aspirin. Transgenic animals expressing the mt-Rosella biosensor in the body wall muscle cells were treated with 1 mM aspirin or vehicle control. Mitophagy induction is signified by the reduction of the ratio between pH-sensitive GFP to pH-insensitive DsRed. Data represent means ± SEM of n = 22--33 worms per group, pooled from two independent experiments (^∗∗∗^p \< 0.001, unpaired t test).

Discussion {#sec3}
==========

Based on the results described in this paper, aspirin may be classified as a CRM. Indeed, aspirin fulfills all the criteria of a CRM ([@bib37]) as it (1) reduces protein acetylation by virtue of its ability to inhibit the acetyltransferase activity of EP300, (2) stimulates autophagic flux, and (3) has no cytotoxic activity.

Caloric restriction-based strategies or periodic fasting have a favorable impact on health and longevity, both in non-human primates ([@bib8], [@bib40]) and in human studies ([@bib35]), although studies carried out in different research centers yielded controversial results regarding CR-mediated improved survival outcomes in rhesus monkeys ([@bib39]). CRMs have been efficiently used to sensitize tumor cells to chemotherapy ([@bib51]), to treat obesity and metabolic syndrome ([@bib5]), and to prolong health span and lifespan ([@bib14], [@bib15], [@bib37]). Aspirin is known to reduce the occurrence and progression of several human cancer types ([@bib34], [@bib53]), to reverse high-fat diet-induced insulin resistance ([@bib28]), and to prolong lifespan in mice ([@bib60]). At this point, it remains to be determined to which extent EP300 inhibition and autophagy activation may effectively contribute to these aspirin effects that apparently transcend its well-established anti-inflammatory effects. Pre-clinical evidence suggests that a brain-permeable aspirin derivative can reduce tau-mediated neurodegeneration in an EP300-dependent fashion ([@bib43]). However, the role of autophagy has not been explored in this setting. Epidemiological and experimental data indicate that a high nutritional uptake of the EP300 inhibitor spermidine counteracts cardiac aging, both in humans and rodents ([@bib14], [@bib15]). In addition, spermidine reduces arteriosclerosis ([@bib42]) and colon carcinogenesis ([@bib41]) in mouse models. These spermidine effects hence show a notable overlap with those of aspirin, in accord with the observation that both compounds inhibit EP300.

EP300 is a protein that undergoes cytoplasmic-nuclear shuttling and that presumably has rather distinct functions in the cytoplasm and in the nucleus. Indeed, in this latter compartment, EP300 acts as co-factor of several major transcription factors, including tumor protein p53 (TP53), cAMP response element-binding protein (CREB), promyelocytic leukemia (PML), and hypoxia-inducible factor 1 alpha subunit (HIF-1α) ([@bib7]). While the immediate autophagy-inducing function of EP300 can be explained by its cytoplasmic action (given that enucleated cells still manifest autophagy induction upon EP300 inhibition) ([@bib38]), it is well possible that the long-term effects of aspirin also involve transcriptional reprogramming ([@bib63]) that is influenced by EP300. Future work will have to address these possibilities.

Untargeted metabolomics analysis revealed that aspirin-derived metabolites are generated in a highly organ-specific fashion, although some metabolites, including salicylate, were found ubiquitously. Future studies are required to identify the molecular structure of all aspirin metabolites and to measure their pharmacological effects. In particular, it will be interesting to learn which aspirin metabolites have autophagy-stimulating properties.

Experimental Procedures {#sec4}
=======================

Mouse Strains and Housing {#sec4.1}
-------------------------

Mice were maintained in specific pathogen-free conditions in a temperature-controlled environment with 12-hr light/dark cycles, and they received food and water *ad libitum* (except as noted). Animal experiments were in compliance with the EU Directive 63/2010 and protocols were approved (APAFIS 2314-2015101617187579v1) by the Ethical Committee of the Cordeliers Research Center (CEEA Darwin 5, registered at the French Ministry of Research). The 6- to 7-week-old male WT C57BL/6 mice were obtained from Envigo France (Gannat, France). For cardiac mitophagy assessment, transgenic mice with cardiac-specific expression of Mito-Keima were generated on a C57BL/6J background with the murine α-myosin heavy-chain promoter (experiments were approved by the Rutgers-New Jersey Medical School's Institutional Animal Care and Use Committee). For the evaluation of the autophagic flux, transgenic mice with cardiac-specific expression of tf-LC3 (Tg-tf-LC3) were generated on an FVB background with the murine α-myosin heavy-chain promoter, kindly provided by Dr. L. Robbins (Children's Hospital, Cincinnati, OH) (experiments were approved by the Rutgers-New Jersey Medical School's Institutional Animal Care and Use Committee).

*In Vitro* Acetylation Assay {#sec4.2}
----------------------------

Recombinant GST-EP300 fusion protein, corresponding to the amino acids 1,066--1,707 (14-418, Millipore), was assessed for its acetyltransferase activity on the EP300 natural substrates recombinant histone H3 protein (M2503S, New England Biolabs). Briefly, 1 μg EP300 Histone acetyl transferase (HAT) domain was incubated in the presence of an HAT assay buffer (250 mM Tris-HCl \[pH 8.0\], 50% glycerol, 0.5 mM EDTA, and 5 mM dithiothreitol), 1 μg substrate protein, and two different concentrations of AcCoA (A2056, Sigma-Aldrich) for 1 hr at 30°C in the presence of AA, C646, and sodium salicylate. The reaction was stopped by adding 4× SDS buffer and boiling the samples. Acetylation of substrate proteins was measured by immunoblotting using specific antibodies against H3K56.

AHA-Protein Labeling {#sec4.3}
--------------------

L-azidohomoalanine (L-AHA) (C10102, Thermo Fisher Scientific) labeling to measure autophagic protein degradation was performed as described in [@bib64], except with an extension of chase time to 18 hr in adaptation to U2OS cells. After chase, U2OS cells were treated for 16 hr in the presence of 5 mM sodium salicylate or nutrient-free medium. Chemoselective ligation between an AHA azido moiety and a fluorescently tagged alkyne probe was used to monitor fluoresence intensity per cell using an automated microscope Image Xpress Micro XLS (Molecular Devices).

Quantification and Statistical Analysis {#sec4.4}
---------------------------------------

Unless otherwise specified, quantitative data are presented as mean ± SD and significance was assessed by unpaired t test by means of Prism software. Additional details are available in the corresponding figure legends and in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S6Table S1. Quantification of Immunoblot Analyses of Autophagic Flux Depicted in Figures 2B, S1B--S1F, S2A, and S2BData represent averaged Fold Change ± SEM n values refer to the number of independent experiments. p values have been calculated by means of the unpaired *t* test, as indicated in Supplemental Experimental Procedures.Table S2. Raw Data from Metabolomics Analysis Performed on Unlabeled Aspirin versus Control and \[^13^C\]-Aspirin versus Aspirin, Related to Figures 5, S5, and S6Each metabolite is annotated for its mass and retention time. For each metabolite, p values and Fold change for each comparison are depicted.Document S2. Article plus Supplemental Information
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